Well-matched contest in basal insulin market between Sanofi and Novo Nordisk

Competition is getting fiercer in the market of next-generation basal insulin which might replace Lantus. Sanofi and Novo Nordisk are even having a publicity war to show off their companies’ performances.

Novo Nordisk Korea announced its next-generation basal insulin product ‘Tresiba Flextouch Inj’ recorded 13.1% in the 2^nd quarter’s market share, increased by about double compared to the 1^st ...